Take a look at some of Wednesday's midday movers:
King Digital Entertainment fell in its market debut after 22.2 million shares were priced at $22.50 a share. The company, which is the maker of "Candy Crush" game, is now valued at about $6 billion.
Nord Anglia Education rose in its market debut after the Hong Kong based school operator was priced at $16 a share. It is valued at about $1.7 billion.
Plug Power plummeted as its CEO said his comments Tuesday about a major deal being announced in two to three weeks were misinterpreted. The deal had been announced two weeks ago.
Tesla Motors moved lower after UBS began coverage with a neutral rating, saying most of the upside is already priced in.
Garmin moved higher after Citigroup upgraded the stock to buy from neutral with a price target of $65 a share (from $50). It cited a positive outlook for the company's new fitness activity monitor, Vivofit, which is worn on the wrist.
Corning rose after Susquehanna upgraded the stock to positive from neutral with a price target of $25 (from $15) citing positive TV trends.
Laboratory Corporation of America and Quest Diagnostics moved higher after research firm ISI made positive comments regarding the House agreeing to forestall a looming 24 percent cut in Medicare payments to doctors.
Oculus Innovative Services and Oculus Vision Tech surged after investors confused the two with privately held Oculus that Facebook agreed to buy for $2 billion. Both companies have very small market caps.
Darden Restaurants moved a bit higher after shareholder Barington Capital called for the company to find a new CEO. The hedge fund, along with Starboard Value, have opposed Darden's plan to spin off its Red Lobster restaurant chain.
Keurig Green Mountain climbed after KeyBanc said the company is successfully converting non-licensed Keurig users to licensed users.
Global Cash Access Holdings sank after the provider of cash access services to the gaming industry said it would not renew its agreement with Caesars.
Francesca's Holdings lost ground after the women's boutique retailer reported weaker than expected fourth-quarter earnings and revenue as comp sales decreased 6 percent.
Insmed fell after the company said its only experimental drug failed a mid-stage trial on patients with a form of bacterial lung infection.
(Read More: )
—By CNBC's Rich Fisherman.
Questions? Comments? Email us at email@example.com